Researchers at the Cleveland Clinic recently completed a decade-long study that followed long-term toxicity results in patients treated with stereotactic body radiation therapy for medically inoperable, early-stage lung cancer.
The study demonstrated that SBRT can reduce the growth and spread of a primary, early-stage lung tumor while minimizing radiation exposure to healthy tissue.
The data from this study provided substantial evidence that treatment with SBRT for early-stage lung cancer results in no high-grade toxicity in the majority of patients treated and provides additional support for SBRT as a viable treatment option for this type of disease. Read the full study here.
Columbus CyberKnife uses SBRT to treat primary and metastatic lung tumors with CyberKnife® technology, an advanced radiosurgery platform that delivers tightly controlled, high-dose radiation to tumors without sedation or incisions. For patients with medically inoperable lung tumors who are seeking a treatment method that may have a low impact on quality of life, treatment with CyberKnife may be an important option. Click here to learn more about key benefits, or contact our center to learn more about SBRT as a treatment option.
This is not intended as medical advice to replace the expertise and judgment of your health care team. It is intended to help you and your family make informed decisions, together with your doctor.